AIM ImmunoTech receives noncompliance notification from NYSE

AIM ImmunoTech (AIM) announced the receipt of a warning notification from the NYSE stating that the company is not in compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide requiring stockholders’ equity of $4M or more if the company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6M or more if the company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of March 31, the company had a stockholders’ deficit of negative $3.9M and has had losses in the most recent five fiscal years ended December 31, 2024.